Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 M

 

to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities

Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003

Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs

Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance

Company to host conference call on January 28, 2025, at 8:30 AM ET

Lantheus will hold a conference call on Tuesday, January 28, 2025, at 8:30 AM ET. To access the live conference via webcast, please register here. A replay will be available after the conclusion of the call on Lantheus' investor website at: https://investor.lantheus.com/news-events/calendar-of-events.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

https://www.prnewswire.com/news-releases/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader-302361401.html